Literature DB >> 22841347

The role of induced pluripotent stem cells in research and therapy of primary immunodeficiencies.

Katja G Weinacht1, Patrick M Brauer, Kerstin Felgentreff, Alex Devine, Andrew R Gennery, Silvia Giliani, Waleed Al-Herz, Axel Schambach, Juan Carlos Zúñiga-Pflücker, Luigi D Notarangelo.   

Abstract

The advent of reprogramming technology has greatly advanced the field of stem cell biology and nurtured our hope to create patient specific renewable stem cell sources. While the number of reports of disease specific induced pluripotent stem cells is continuously rising, the field becomes increasingly more aware that induced pluripotent stem cells are not as similar to embryonic stem cells as initially assumed. Our state of the art understanding of human induced pluripotent stem cells, their capacity, their limitations and their promise as it pertains to the study and treatment of primary immunodeficiencies, is the content of this review.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 22841347      PMCID： PMC3478496          DOI： 10.1016/j.coi.2012.07.001

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  64 in total

1.  A feeder-free and efficient production of functional neutrophils from human embryonic stem cells.

Authors:  Koichi Saeki; Kumiko Saeki; Masako Nakahara; Satoko Matsuyama; Naoko Nakamura; Yoshiko Yogiashi; Asako Yoneda; Makoto Koyanagi; Yasushi Kondo; Akira Yuo
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

2.  Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.

Authors:  Jizhong Zou; Prashant Mali; Xiaosong Huang; Sarah N Dowey; Linzhao Cheng
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

3.  Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming.

Authors:  Eva Warlich; Johannes Kuehle; Tobias Cantz; Martijn H Brugman; Tobias Maetzig; Melanie Galla; Adam A Filipczyk; Stephan Halle; Hannes Klump; Hans R Schöler; Christopher Baum; Timm Schroeder; Axel Schambach
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

4.  Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells.

Authors:  Kyung-Dal Choi; Maxim Vodyanik; Igor I Slukvin
Journal:  Nat Protoc       Date:  2011-02-17       Impact factor: 13.491

5.  Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment.

Authors:  Faiyaz Notta; Sergei Doulatov; Elisa Laurenti; Armando Poeppl; Igor Jurisica; John E Dick
Journal:  Science       Date:  2011-07-08       Impact factor: 47.728

6.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases.

Authors:  Fyodor D Urnov; Jeffrey C Miller; Ya-Li Lee; Christian M Beausejour; Jeremy M Rock; Sheldon Augustus; Andrew C Jamieson; Matthew H Porteus; Philip D Gregory; Michael C Holmes
Journal:  Nature       Date:  2005-04-03       Impact factor: 49.962

Review 7.  Induced pluripotent stem cells in clinical hematology: potentials, progress, and remaining obstacles.

Authors:  Athanasia D Panopoulos; Juan C I Belmonte
Journal:  Curr Opin Hematol       Date:  2012-07       Impact factor: 3.284

8.  T lineage differentiation from human embryonic stem cells.

Authors:  Zoran Galic; Scott G Kitchen; Amelia Kacena; Aparna Subramanian; Bryan Burke; Ruth Cortado; Jerome A Zack
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-14       Impact factor: 11.205

9.  iPS cells produce viable mice through tetraploid complementation.

Authors:  Xiao-yang Zhao; Wei Li; Zhuo Lv; Lei Liu; Man Tong; Tang Hai; Jie Hao; Chang-long Guo; Qing-wen Ma; Liu Wang; Fanyi Zeng; Qi Zhou
Journal:  Nature       Date:  2009-09-03       Impact factor: 49.962

10.  Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity.

Authors:  Petter S Woll; Bartosz Grzywacz; Xinghui Tian; Rebecca K Marcus; David A Knorr; Michael R Verneris; Dan S Kaufman
Journal:  Blood       Date:  2009-04-13       Impact factor: 22.113
View more
  5 in total

1.  Modeling altered T-cell development with induced pluripotent stem cells from patients with RAG1-dependent immune deficiencies.

Authors:  Patrick M Brauer; Itai M Pessach; Erik Clarke; Jared H Rowe; Lisa Ott de Bruin; Yu Nee Lee; Carmen Dominguez-Brauer; Anne M Comeau; Geneve Awong; Kerstin Felgentreff; Yuhang H Zhang; Andrea Bredemeyer; Waleed Al-Herz; Likun Du; Francesca Ververs; Marion Kennedy; Silvia Giliani; Gordon Keller; Barry P Sleckman; David G Schatz; Frederic D Bushman; Luigi D Notarangelo; Juan Carlos Zúñiga-Pflücker
Journal:  Blood       Date:  2016-06-14       Impact factor: 22.113

2.  A novel common gamma chain mutation in a Chinese family with X-linked severe combined immunodeficiency (X-SCID; T(-)NK(-)B(+)).

Authors:  Weiping Tan; Sifei Yu; Jiaying Lei; Baojing Wu; Changyou Wu
Journal:  Immunogenetics       Date:  2015-09-26       Impact factor: 2.846

3.  Bottlenecks in deriving definitive hematopoietic stem cells from human pluripotent stem cells: a CIRM mini-symposium and workshop report.

Authors:  Kelly A Shepard; Sohel Talib
Journal:  Stem Cells Transl Med       Date:  2014-07       Impact factor: 6.940

Review 4.  Deciphering Human Cell-Autonomous Anti-HSV-1 Immunity in the Central Nervous System.

Authors:  Fabien G Lafaille; Michael J Ciancanelli; Lorenz Studer; Gregory Smith; Luigi Notarangelo; Jean-Laurent Casanova; Shen-Ying Zhang
Journal:  Front Immunol       Date:  2015-05-08       Impact factor: 7.561

Review 5.  Granule protein processing and regulated secretion in neutrophils.

Authors:  Avinash Sheshachalam; Nutan Srivastava; Troy Mitchell; Paige Lacy; Gary Eitzen
Journal:  Front Immunol       Date:  2014-09-19       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.